Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Treasury Shares (2022 - 2025)

Protara Therapeutics' Treasury Shares history spans 4 years, with the latest figure at $571145.0 for Q4 2025.

  • Quarterly Treasury Shares rose 93.01% to $571145.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $571145.0 through Dec 2025, up 93.01% year-over-year, with the annual reading at $571145.0 for FY2025, 93.01% up from the prior year.
  • Treasury Shares came in at $571145.0 for Q4 2025, up from $555245.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $571145.0 in Q4 2025 to a low of $196838.0 in Q4 2022.
  • The 4-year median for Treasury Shares is $319404.5 (2024), against an average of $368608.2.
  • The largest YoY upside for Treasury Shares was 93.01% in 2025 against a maximum downside of 12.16% in 2025.
  • Protara Therapeutics' Treasury Shares stood at $196838.0 in 2022, then grew by 20.24% to $236679.0 in 2023, then increased by 25.03% to $295914.0 in 2024, then surged by 93.01% to $571145.0 in 2025.
  • Per Business Quant, the three most recent readings for TARA's Treasury Shares are $571145.0 (Q4 2025), $555245.0 (Q3 2025), and $510945.0 (Q2 2025).